UNSPSC 51202600: Immunosupressant imides

This classification denotes organic substances consisting of two acyl groups bound to nitrogen, substances called imides, that reduce a human host's humoral and/or cell-mediated defense mechanisms against deviant native cells, foreign organisms, or foreign substances (the human immune response and system thereof), thus the term IMMUNOSUPRESSANT IMIDES.

UNSPSC 51202600 Immunosuppressant imides is a Class code that in recent state and local procurement activity spans pharmaceutical supply chain transactions, though the opportunities posted under this code show limited direct alignment with the nominal immunosuppressant scope. State and local health departments and county health authorities are using this code to procure pharmaceutical products through piggyback and direct-award mechanisms, often via established cooperative purchasing consortia such as MMCAP Infuse. The Illinois Department of Public Health awarded a $2,999,999.11 contract to Chartwell Rx LLC through MMCAP Infuse on August 28, 2026, for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets under an Invitation for Bid process, with a 12-month initial term and renewal options through year three. Pharmaceutical warehouse orders and bulk supply agreements dominate the activity, with vendors competing on price and responsiveness in low-risk commodity bidding environments where no set-aside or preference programs are typically applied.

Geographic activity centers in Florida and Illinois based on recent opportunities. Seminole County, Florida released an IFB on June 30, 2026, to procure 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, a two-year initial term, and one-year renewal option. The Naloxone solicitation, while tagged to this code, reflects community health and emergency response procurement rather than immunosuppressant pharmaceutical supply, indicating potential code-tagging variation in state and local systems. Opportunities under this code typically move through established e-Procurement portals with fixed-fee pricing, inclusive shipping costs, standard compliance requirements (E-Verify, drug-free workplace certification, insurance coverage), and probationary periods. Recent activity shows limited volume — two recorded opportunities in the past four months — suggesting this code experiences lower procurement velocity than broader pharmaceutical or health-supply families.